Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Kumlesh K. Dev"'
Autor:
Sibylle Béchet, Kumlesh K. Dev
Publikováno v:
Biomedicines, Vol 12, Iss 3, p 594 (2024)
Krabbe’s disease (KD) is caused by mutations in the lysosomal enzyme galactocerebrosidase and is associated with psychosine toxicity. The sphingosine 1-phosphate receptor (S1PR) agonist fingolimod (FTY720) attenuates psychosine-induced cell death o
Externí odkaz:
https://doaj.org/article/0c27225b275e48fd9c2e0f6a978dd73e
Autor:
Kapil Sharma, Kumlesh K. Dev
Publikováno v:
Biomedicines, Vol 11, Iss 5, p 1313 (2023)
The role of altered myelin in the onset and development of schizophrenia and changes in myelin due to antipsychotics remains unclear. Antipsychotics are D2 receptor antagonists, yet D2 receptor agonists increase oligodendrocyte progenitor numbers and
Externí odkaz:
https://doaj.org/article/9520d84fc0c842e5b97d20dd2c55f976
Autor:
Jennifer Moran, Eimear Mylod, Laura E. Kane, Caroline Marion, Emily Keenan, Marianna Mekhaeil, Joanne Lysaght, Kumlesh K. Dev, Jacintha O’Sullivan, Melissa J. Conroy
Publikováno v:
Pharmaceutics, Vol 15, Iss 2, p 360 (2023)
Glioblastoma multiforme (GBM) is the most common adult primary brain malignancy, with dismal survival rates of ~14.6 months. The current standard-of-care consists of surgical resection and chemoradiotherapy, however the treatment response is limited
Externí odkaz:
https://doaj.org/article/7c0190764d2e4db88ffa5da6ec031cef
Publikováno v:
Journal of Neuroinflammation, Vol 14, Iss 1, Pp 1-12 (2017)
Abstract Background The G protein-coupled receptor EBI2 (Epstein-Barr virus-induced gene 2) is activated by 7α, 25-dihydroxycholesterol (7α25HC) and plays a role in T cell-dependant antibody response and B cell migration. Abnormal EBI2 signaling is
Externí odkaz:
https://doaj.org/article/e396bcb16b034cb99bc68498841f56c1
Autor:
Maria Velasco-Estevez, Nina Koch, Ilona Klejbor, Stephane Laurent, Kumlesh K. Dev, Andrzej Szutowicz, Andreas W. Sailer, Aleksandra Rutkowska
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 9, p 4342 (2021)
The EBI2 receptor regulates the immune system and is expressed in various immune cells including B and T lymphocytes. It is also expressed in astrocytes in the central nervous system (CNS) where it regulates pro-inflammatory cytokine release, cell mi
Externí odkaz:
https://doaj.org/article/433802bd5d95420e946fde4cde7f4623
Autor:
Sinead A. O’Sullivan, Kumlesh K. Dev
Publikováno v:
Journal of Neuroinflammation, Vol 14, Iss 1, Pp 1-9 (2017)
Abstract Background Fractalkine/CX3CR1 signalling has been implicated in many neurodegenerative and neurological diseases of the central nervous system (CNS). This signalling pathway plays an important role in regulating reactive oxygen species (ROS)
Externí odkaz:
https://doaj.org/article/b6b262dcf4464a7bb6044003f8dee3c7
Autor:
Sergey Neyman, Karl-Heinz Braunewell, Kara E. O’Connell, Kumlesh K. Dev, Denise Manahan-Vaughan
Publikováno v:
Frontiers in Synaptic Neuroscience, Vol 11 (2019)
The group I metabotropic glutamate (mGlu) receptor subtypes, mGlu1 and mGlu5, strongly regulate hippocampal synaptic plasticity. Both harbor PSD-95/discs-large/ZO-1 (PDZ) motifs at their extreme carboxyl terminals, which allow interaction with the PD
Externí odkaz:
https://doaj.org/article/7d229a529de14c2fb0524012b88878e9
Autor:
María Velasco-Estevez, Myrthe Mampay, Hervé Boutin, Aisling Chaney, Peter Warn, Andrew Sharp, Ellie Burgess, Emad Moeendarbary, Kumlesh K. Dev, Graham K. Sheridan
Publikováno v:
Frontiers in Aging Neuroscience, Vol 10 (2018)
A defining pathophysiological hallmark of Alzheimer’s disease (AD) is the amyloid plaque; an extracellular deposit of aggregated fibrillar Aβ1-42 peptides. Amyloid plaques are hard, brittle structures scattered throughout the hippocampus and cereb
Externí odkaz:
https://doaj.org/article/4df186f4fb1d4111b88addf82ee99b77
Publikováno v:
Molecular Neurobiology. 59:1882-1895
Therapeutic strategies for Alzheimer’s disease (AD) have largely focused on the regulation of amyloid pathology while those targeting tau pathology, and inflammatory mechanisms are less explored. In this regard, drugs with multimodal and concurrent
Publikováno v:
Neurotherapeutics
Polymeric nanoparticles are being extensively investigated as an approach for brain delivery of drugs, especially for their controlled release and targeting capacity. Nose-to-brain administration of nanoparticles, bypassing the blood brain barrier, o